Personalized pharmacogenomics: predicting efficacy and adverse drug reactions
- PMID: 24898040
- DOI: 10.1146/annurev-genom-090413-025419
Personalized pharmacogenomics: predicting efficacy and adverse drug reactions
Abstract
Drug response varies between individuals owing to disease heterogeneity, environmental factors, and genetic factors. Genetic factors can affect both the pharmacokinetics and pharmacodynamics of a drug, leading to changes in local and systemic drug exposure and/or changes in the function of the drug target, altering drug response. Several pharmacogenetic biomarkers are already utilized in clinical practice and have been shown to improve clinical outcomes. However, a large number of other biomarkers have never made it beyond the discovery stage. Concerted effort is needed to improve the translation of pharmacogenetic biomarkers into clinical practice, and this will involve the use of standardized phenotyping and genotyping strategies, collaborative work, multidisciplinary approaches to identifying and replicating associations, and cooperation with industry to facilitate translation and commercialization. Acceptance of these approaches by clinicians, regulators, patients, and the public will be important in determining future success.
Keywords: biomarkers; drug efficacy; drug safety; personalized medicine; pharmacogenomics.
Similar articles
-
Pharmacogenetic Markers of Drug Efficacy and Toxicity.Clin Pharmacol Ther. 2015 Jul;98(1):61-70. doi: 10.1002/cpt.135. Epub 2015 Jun 3. Clin Pharmacol Ther. 2015. PMID: 25870137 Review.
-
Report on the pharmacogenomics and personalized medicine 2011 conference: part 1.Pharmacogenomics. 2012 Jan;13(2):141-5. doi: 10.2217/pgs.11.180. Pharmacogenomics. 2012. PMID: 22256866
-
Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.Curr Pharm Biotechnol. 2017;18(3):274-281. doi: 10.2174/1389201018666170207124835. Curr Pharm Biotechnol. 2017. PMID: 28176638
-
Pharmacogenomics: Prescribing Precisely.Med Clin North Am. 2019 Nov;103(6):977-990. doi: 10.1016/j.mcna.2019.07.002. Epub 2019 Aug 24. Med Clin North Am. 2019. PMID: 31582008 Review.
-
The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.Thyroid. 2010 Jul;20(7):681-7. doi: 10.1089/thy.2010.1642. Thyroid. 2010. PMID: 20578893 Review.
Cited by
-
Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression.Hum Genet. 2020 Feb;139(2):137-149. doi: 10.1007/s00439-019-02093-7. Epub 2019 Nov 30. Hum Genet. 2020. PMID: 31786673
-
Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms.Pharmacogenomics J. 2019 Dec;19(6):516-527. doi: 10.1038/s41397-019-0096-y. Epub 2019 Oct 3. Pharmacogenomics J. 2019. PMID: 31578463 Free PMC article.
-
Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System.Front Genet. 2021 Oct 20;12:712602. doi: 10.3389/fgene.2021.712602. eCollection 2021. Front Genet. 2021. PMID: 34745204 Free PMC article. Review.
-
Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model.Front Pharmacol. 2022 Jun 28;13:918493. doi: 10.3389/fphar.2022.918493. eCollection 2022. Front Pharmacol. 2022. PMID: 36120299 Free PMC article.
-
Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants.Eur J Clin Pharmacol. 2023 Oct;79(10):1315-1320. doi: 10.1007/s00228-023-03540-1. Epub 2023 Jul 17. Eur J Clin Pharmacol. 2023. PMID: 37458773
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical